Atlas Trials

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

Clinical trial NCT06664996 · RECRUITING

Trial details

NCT number
NCT06664996
Sponsor
West China Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2024-10-15
Primary completion
2025-10-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.